IMMUNE CHECKPOINT INHIBITORS IN SOLID TUMORS: MECHANISMS, CLINICAL EFFICACY, BIOMARKER-GUIDED PATIENT SELECTION, AND IMMUNE-RELATED ADVERSE EVENTS. jmsi 2026, 5 (03), 1709-1714. https://doi.org/10.55640/.